Senseonics (Nasdaq: SENS) completes Eversense CGM asset buys in key EU markets

Rhea-AI Filing Summary

Senseonics Holdings, Inc. has completed the previously announced local asset purchase agreements with Ascensia Diabetes Care for its commercial Eversense continuous glucose monitoring (CGM) activities in several European markets. These transactions cover Eversense CGM commercial assets in Germany, Spain, Sweden and Italy.

The asset purchases in Germany, Spain and Sweden closed on June 1, 2026, and the purchase related to Italy closed on June 8, 2026, with the transfer effective for finance and accounting purposes as of June 1, 2026. This shifts ownership of these commercial assets from Ascensia to Senseonics and its affiliates in the covered countries.

Insights

Medical device sector analyst

Senseonics now directly controls Eversense CGM commercial assets in key European markets.

Senseonics has closed asset purchases from Ascensia Diabetes Care covering Eversense CGM commercial activities in Germany, Spain, Sweden and Italy. This follows a master asset purchase agreement signed on December 31, 2025, and local agreements dated March 12, 2026.

By acquiring these local commercial assets, Senseonics brings European Eversense CGM activities under the purchaser parties’ ownership rather than relying on the seller parties. The filing notes closings occurred on June 1, 2026 and June 8, 2026, with an effective accounting transfer date of June 1, 2026.

While no financial terms are disclosed here, direct control of commercial assets in four European countries may influence how the company manages sales, marketing and support for Eversense CGM. Subsequent company filings may provide additional detail on financial impact and integration progress.

8-K Event Classification

Item 8.01 — Other Events

1 item

Item 8.01 Other Events Other

Voluntary disclosure of events the company deems important to shareholders but not covered by other items.

Key Terms

local asset purchase agreements, master asset purchase agreement, customary closing conditions, Eversense CGM activities

4 terms

local asset purchase agreements financial

"the Company, Senseonics, Incorporated ... entered into a series of local asset purchase agreements on March 12, 2026"

master asset purchase agreement financial

"as contemplated by that certain master asset purchase agreement, dated as of December 31, 2025"

customary closing conditions financial

"Following the satisfaction or waiver of customary closing conditions, the closing of each of the European Asset Purchases"

"Customary closing conditions" are standard rules or checks that must be met before a business deal can be finalized, like making sure all paperwork is in order or that certain approvals are obtained. They matter because they help protect both parties, ensuring everything is in place and reducing the risk of surprises or problems after the deal is closed.

Eversense CGM activities medical

"assets related to Seller’s commercial Eversense CGM activities in Italy, Germany, Spain and Sweden"

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Understanding 8-K Material Events →

Available on EDGAR 06/08/2026 - 04:06 PM Accepted by SEC EDGAR 06/08/2026 - 04:05 PM Learn about SEC filing dates

FAQ

What did Senseonics (SENS) announce regarding Eversense CGM in Europe?

Senseonics disclosed that it closed several local asset purchase agreements with Ascensia Diabetes Care. These deals transfer commercial assets related to the Eversense CGM system in Germany, Spain, Sweden and Italy to Senseonics and its affiliates under a previously signed master asset purchase agreement.

Which countries are covered by Senseonics’ completed European asset purchases?

The completed asset purchases cover Eversense CGM commercial activities in Germany, Spain, Sweden and Italy. Senseonics and its affiliates will now own the specified commercial assets in these markets, rather than Ascensia and its affiliates, as outlined in the local and master asset purchase agreements.

When did the Senseonics European asset purchases for Eversense CGM close?

Closings for the Eversense CGM asset purchases in Germany, Spain and Sweden occurred on June 1, 2026. The closing for the Italian asset purchase occurred on June 8, 2026, with the effective transfer date for finance and accounting purposes set as June 1, 2026.

Who is selling the European Eversense CGM assets to Senseonics?

Ascensia Diabetes Care Holdings AG and its affiliates are selling the Eversense CGM commercial assets. These entities, described as the seller parties, entered into a master asset purchase agreement and related local asset purchase agreements with Senseonics and its affiliates, referred to as the purchaser parties.

What agreement framework governs the Senseonics European asset purchases?

The transactions are governed by a master asset purchase agreement dated December 31, 2025. Under this, Senseonics and its affiliates agreed to acquire specified Eversense CGM commercial assets from Ascensia and its affiliates, with local asset purchase agreements executed on March 12, 2026 to implement the framework in individual countries.

Does the filing describe any conditions for closing the European asset purchases?

Yes. The filing notes that the closings occurred after satisfaction or waiver of customary closing conditions. While those conditions are not detailed here, this language signals that standard requirements for completing such asset transactions were addressed before ownership of the Eversense CGM assets transferred.

false 0001616543 0001616543 2026-06-01 2026-06-01 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d) OF THE

SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported): June 1, 2026

SENSEONICS HOLDINGS, INC.

(Exact Name of Registrant as Specified in its Charter)

Delaware		001-37717		47-1210911
(State or Other Jurisdiction of Incorporation)		(Commission File Number)		(IRS Employer Identification No.)

20451 Seneca Meadows Parkway
Germantown, MD 20876-7005

(Address of Principal Executive Office) (Zip Code)

Registrant's telephone number, including area code: (301) 515-7260

Not Applicable

Former name or former address, if changed since last report

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2 below):

¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common Stock	SENS	Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ¨

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

Item 8.01 Other Events.

Closing of Local Asset Purchase Agreements

As disclosed in the Current Report on Form 8-K filed by Senseonics Holdings, Inc. (the “Company”) with the Securities and Exchange Commission on March 12, 2026, the Company, Senseonics, Incorporated (together with the Company and its affiliates, the “Purchaser Parties”) and Ascensia Diabetes Care Holdings AG (the “Seller” and together with its affiliates, the “Seller Parties”) entered into a series of local asset purchase agreements on March 12, 2026, pursuant to which, among other things, the Purchaser Parties agreed to acquire Seller’s and as applicable, Seller Parties’, right, title and interest in and to certain assets related to Seller’s commercial Eversense CGM activities in Italy, Germany, Spain and Sweden (such assets, the “European Purchased Assets”) and, in connection therewith, the assumption of certain liabilities and obligations associated with the European Purchased Assets (the “European Asset Purchases”), as contemplated by that certain master asset purchase agreement, dated as of December 31, 2025, by and between the Purchaser Parties and the Seller.

Following the satisfaction or waiver of customary closing conditions, the closing of each of the European Asset Purchases related to the Eversense CGM activities in Germany, Spain and Sweden occurred on June 1, 2026 and the closing of the European Asset Purchase related to the Eversense CGM activities in Italy occurred on June 8, 2026, with an effective date of the transfer for finance and accounting purposes of June 1, 2026.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: June 8, 2026	SENSEONICS HOLDINGS, INC.
	By:	/s/ Rick Sullivan
	Name:	Rick Sullivan
	Title:	Chief Financial Officer

Filing Exhibits & Attachments

3 documents

Other Documents

• EX-101 XBRL TAXONOMY EXTENSION SCHEMA 2.9 KB
• EX-101 XBRL TAXONOMY EXTENSION LABEL LINKBASE 33.4 KB
• EX-101 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE 21.8 KB